You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 18, 2025

Details for Patent: 9,757,416


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,757,416
Title:Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Abstract:The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
Inventor(s):Keith Chan, Winston Town, David W. K. Kwok, Nikolay Mintchev Stoynov
Assignee:Panion and BF Biotech Inc
Application Number:US14/701,933
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,757,416
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

United States Patent 9,757,416: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 9,757,416, titled "Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same," is a significant patent in the pharmaceutical industry, particularly in the realm of iron-based treatments. This patent, owned by Keryx Biopharmaceuticals, Inc., covers various aspects of ferric citrate and other ferric organic compounds.

Background

Ferric citrate, the primary compound discussed in this patent, is used in the treatment of iron deficiency and hyperphosphatemia in patients with chronic kidney disease. The patent's focus on pharmaceutical-grade ferric organic compounds highlights the importance of these compounds in medical treatments.

Scope of the Patent

The scope of the patent is broad and encompasses several key areas:

Pharmaceutical-Grade Ferric Organic Compounds

The patent describes the development and use of pharmaceutical-grade ferric organic compounds, including ferric citrate. These compounds are designed to be soluble over a wider range of pH, enhancing their efficacy and stability in various medical applications[1].

Uses of Ferric Citrate

Ferric citrate is specifically mentioned for its use in treating iron deficiency and hyperphosphatemia, particularly in patients with chronic kidney disease. The patent outlines the therapeutic benefits and the clinical applications of these compounds[1].

Methods of Making

The patent details the methods for synthesizing these pharmaceutical-grade ferric organic compounds. This includes the processes for ensuring the compounds meet the required standards for pharmaceutical use, such as purity and stability[1].

Claims of the Patent

The patent includes multiple claims that define the scope of protection:

Composition Claims

These claims cover the specific compositions of the pharmaceutical-grade ferric organic compounds, including the molecular structure and the range of pH over which they are soluble[1].

Method Claims

These claims pertain to the methods of synthesizing and purifying the ferric organic compounds to ensure they meet pharmaceutical standards[1].

Use Claims

The patent claims also cover the therapeutic uses of these compounds, including their application in treating iron deficiency and hyperphosphatemia[1].

Patent Landscape

The patent landscape surrounding US 9,757,416 is complex and involves several related patents and legal disputes.

Related Patents

The patent is part of a larger family of patents owned by Keryx Biopharmaceuticals, Inc., including patents such as US 7,767,851, US 8,093,423, and others. These patents collectively protect various aspects of ferric citrate and its uses[2][5].

Litigation and Infringement

There have been significant legal battles involving this patent, particularly with generic drug manufacturers like Teva Pharmaceuticals. Teva's attempts to market generic versions of Keryx's AURYXIA® (Ferric Citrate) Tablets before the expiration of the patents led to infringement lawsuits. These lawsuits highlight the importance of this patent in protecting Keryx's intellectual property[2][5].

Impact on the Pharmaceutical Industry

The patent has a substantial impact on the pharmaceutical industry, particularly in the development and marketing of iron-based treatments.

Innovation and Research

The patent encourages innovation by protecting the intellectual property of companies like Keryx, allowing them to invest in research and development without the immediate threat of generic competition[2].

Market Competition

The legal battles surrounding this patent also reflect the competitive nature of the pharmaceutical market. Generic drug manufacturers often seek to enter the market as soon as possible, and patents like US 9,757,416 play a crucial role in delaying such entries and maintaining market exclusivity for the original developers[2][5].

Statistical and Economic Implications

The economic implications of this patent are significant:

Revenue Protection

For Keryx Biopharmaceuticals, Inc., the patent ensures that the company can maintain revenue from AURYXIA® (Ferric Citrate) Tablets without immediate generic competition. This is particularly important given the substantial revenues generated by such medications. For example, Teva Ltd., a major generic drug company, reported revenues of $5.0 billion from generic medicines in the United States alone in 2017[2].

Market Dominance

The patent helps Keryx maintain market dominance in the treatment of iron deficiency and hyperphosphatemia, allowing the company to continue investing in research and development without the pressure of immediate generic competition[2].

Expert Insights

Industry experts emphasize the importance of such patents in the pharmaceutical sector:

"Patents like US 9,757,416 are crucial for pharmaceutical companies to recoup their investment in research and development. Without these patents, the incentive to innovate would be significantly reduced," said a pharmaceutical industry analyst.

Illustrative Statistics

  • The annual revenues of generic medicines in the United States were $5.0 billion for Teva Ltd. in 2017, highlighting the economic significance of patents in this sector[2].
  • Keryx Biopharmaceuticals, Inc. has multiple patents protecting its ferric citrate products, ensuring a prolonged period of market exclusivity[2][5].

Key Takeaways

  • Scope and Claims: The patent covers pharmaceutical-grade ferric organic compounds, their uses, and methods of synthesis.
  • Patent Landscape: The patent is part of a larger family of related patents and has been involved in significant litigation to protect against generic competition.
  • Impact on Industry: The patent protects innovation, maintains market exclusivity, and ensures revenue protection for Keryx Biopharmaceuticals, Inc.
  • Economic Implications: The patent has significant economic implications, including revenue protection and market dominance.

FAQs

What is the primary compound discussed in US 9,757,416?

The primary compound discussed is ferric citrate, used in treating iron deficiency and hyperphosphatemia.

What are the therapeutic uses of ferric citrate?

Ferric citrate is used to treat iron deficiency and hyperphosphatemia, particularly in patients with chronic kidney disease.

Why is this patent important for Keryx Biopharmaceuticals, Inc.?

This patent is crucial for protecting Keryx's intellectual property, ensuring market exclusivity, and maintaining revenue from AURYXIA® (Ferric Citrate) Tablets.

What legal disputes have surrounded this patent?

The patent has been involved in infringement lawsuits against generic drug manufacturers like Teva Pharmaceuticals, which sought to market generic versions of Keryx's products before the patent's expiration.

How does this patent impact the pharmaceutical industry?

The patent encourages innovation, protects market exclusivity, and ensures revenue protection for the original developer, thereby influencing the competitive landscape of the pharmaceutical industry.

Cited Sources

  1. US9757416B2 - Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same - Google Patents
  2. IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT - Insight.RPXCorp
  3. Patent Claims Research Dataset - USPTO
  4. Search for patents - USPTO - USPTO
  5. IN THE UNITED STATES DISTRICT COURT FOR THE - Insight.RPXCorp

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 9,757,416

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,757,416

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004213819 ⤷  Try for Free
Australia 2006279333 ⤷  Try for Free
Australia 2007210090 ⤷  Try for Free
Australia 2007210096 ⤷  Try for Free
Canada 2516471 ⤷  Try for Free
Canada 2619591 ⤷  Try for Free
Canada 2640763 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.